Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Early Alzheimer's Disease
NEJM 349:1056-1063, Kawas,C.H., 2003
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
High-Dose Estradiol Improves Cognition for Women with AD, Results of a Randomized Study
Neurol 57:605-612, Asthana,S.,et al, 2001
Immunologic Treatment of Alzheimer's Disease
NEJM 341:1694-1695, Blass,J.P., 1999
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Multicenter Trial of Naloxone in Alzheimer's Disease
Ann Neurol 25:404-406, Henderson,V.W.,et al, 1989
Memory Enhancement with Oral Physostigmine in Alzheimer's Disease
NEJM 308:720-721, Thal,L.J.,et al, 1983
Effects of Naloxone in Senile Dementia:A Double-Blind Trial
NEJM 308:721-722, Reisberg,B.,et al, 1983
An Overview of Pharmacologic Treatment of Cognitive Decline in the Aged
Am J Psychiatry 138:593-600, Reisberg,B.,et al, 1981